RS57567B1 - Kombinovana terapija za lečenje multiple skleroze - Google Patents

Kombinovana terapija za lečenje multiple skleroze

Info

Publication number
RS57567B1
RS57567B1 RS20180737A RSP20180737A RS57567B1 RS 57567 B1 RS57567 B1 RS 57567B1 RS 20180737 A RS20180737 A RS 20180737A RS P20180737 A RSP20180737 A RS P20180737A RS 57567 B1 RS57567 B1 RS 57567B1
Authority
RS
Serbia
Prior art keywords
treatment
multiple sclerosis
combination therapy
therapy
sclerosis
Prior art date
Application number
RS20180737A
Other languages
English (en)
Inventor
Theis Terwey
Roland Rupp
Peder M Andersen
Original Assignee
Fwp Ip Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fwp Ip Aps filed Critical Fwp Ip Aps
Publication of RS57567B1 publication Critical patent/RS57567B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RS20180737A 2012-08-03 2013-08-02 Kombinovana terapija za lečenje multiple skleroze RS57567B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
US201261712008P 2012-10-10 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
EP13745073.0A EP2879672B1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
RS57567B1 true RS57567B1 (sr) 2018-10-31

Family

ID=47008405

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180737A RS57567B1 (sr) 2012-08-03 2013-08-02 Kombinovana terapija za lečenje multiple skleroze

Country Status (20)

Country Link
US (2) US20150164849A1 (sr)
EP (4) EP2692343A1 (sr)
JP (2) JP2015523407A (sr)
KR (3) KR20200142597A (sr)
CN (3) CN113288891A (sr)
AU (3) AU2013298517A1 (sr)
CA (2) CA3107367A1 (sr)
DK (1) DK2879672T3 (sr)
EA (1) EA201590166A8 (sr)
ES (1) ES2674947T3 (sr)
HK (1) HK1211210A1 (sr)
HR (1) HRP20180939T1 (sr)
HU (1) HUE038382T2 (sr)
LT (1) LT2879672T (sr)
PL (1) PL2879672T3 (sr)
PT (1) PT2879672T (sr)
RS (1) RS57567B1 (sr)
SI (1) SI2879672T1 (sr)
TR (1) TR201808859T4 (sr)
WO (1) WO2014020156A1 (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
CN114401742B (zh) * 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms
US20230099229A1 (en) * 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915334A2 (en) 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
UA112975C2 (uk) * 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
ES2555279T3 (es) 2010-02-12 2015-12-30 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Also Published As

Publication number Publication date
JP2018150375A (ja) 2018-09-27
JP2015523407A (ja) 2015-08-13
EP3398595A1 (en) 2018-11-07
EA201590166A8 (ru) 2015-10-30
CA3107367A1 (en) 2014-02-06
TR201808859T4 (tr) 2018-07-23
HRP20180939T1 (hr) 2018-12-14
CA2880742A1 (en) 2014-02-06
EP2879672B1 (en) 2018-04-11
CA2880742C (en) 2021-03-16
US20190091190A1 (en) 2019-03-28
CN104684553A (zh) 2015-06-03
AU2013298517A1 (en) 2015-03-05
AU2018201801B2 (en) 2019-11-21
DK2879672T3 (en) 2018-07-30
SI2879672T1 (sl) 2018-10-30
KR20150040338A (ko) 2015-04-14
CN107669668A (zh) 2018-02-09
AU2018201801A1 (en) 2018-04-05
US20150164849A1 (en) 2015-06-18
LT2879672T (lt) 2018-07-10
AU2020201290A1 (en) 2020-03-12
HUE038382T2 (hu) 2018-10-29
KR20210147083A (ko) 2021-12-06
PL2879672T3 (pl) 2018-10-31
EP2879672A1 (en) 2015-06-10
EP2692343A1 (en) 2014-02-05
ES2674947T3 (es) 2018-07-05
EP2692344A1 (en) 2014-02-05
HK1211210A1 (en) 2016-05-20
PT2879672T (pt) 2018-07-03
WO2014020156A1 (en) 2014-02-06
AU2020201290B2 (en) 2021-08-19
EA201590166A1 (ru) 2015-06-30
KR20200142597A (ko) 2020-12-22
CN113288891A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
EP2906208A4 (en) THERAPEUTIC TREATMENT
HK1206937A1 (en) Methods of administering pirfenidone therapy
ZA201408820B (en) Use of high dose laquinimod for treating multiple sclerosis
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL275636A (en) Medical combination for cancer treatment
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
IL233495A0 (en) Combination for cancer treatment
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer